In this study, adolescent fasting plasma glucose in the high-normal range was associated with poorer brain structure and function in midlife irrespective of midlife fasting plasma glucose values.
Introduction
Type 2 diabetes mellitus (T2DM) is present in over 25% of US adults aged 65 years or older and prediabetes is present in more than 48%. 1,2 T2DM doubles the risk of cognitive impairment and dementia and greatly increases health care needs and costs. 3 Similarly, prediabetes increases risk for dementia 4 . However, it remains unclear whether improving glycemic control is a viable approach for reducing risk of cognitive impairment in prediabetes or T2DM
5-10 11-18 . One reason for inconsistencies in the relationship between cognitive outcomes and glycemic control is that lifespan exposures to the metabolic disturbances associated with T2DM, as well as clinically-silent brain injury, are rarely accounted for. The progression from cardiometabolic risk factors, to insulin resistance, to the beta cell dysfunction and hyperglycemia that characterize T2DM, develops insidiously over decades, starting as early as childhood 19, 20 . Similarly, the brain changes that culminate in Alzheimer-related and vascular-related neuropathology develop insidiously over many years 21, 22 . T2DM-related and cognitive-decline-related biological mechanisms may interact to impact the brain in complex ways during their progression 23-28 29,30 . Thus, it is possible that metabolic disturbances as early as childhood could influence brain health and cognitive functioning decades later, independent of metabolic status at that later time [31] [32] [33] [34] [35] . However, at this time it is not clear what effect, if any, metabolic exposures in childhood and young adulthood may have on brain health and cognitive function in midlife and old age.
One specific unknown is whether clinical thresholds for identifying prediabetes and T2DM are adequate to identify children and young adults at increased risk of adverse brain outcomes decades later. Fasting plasma glucose (FPG) thresholds for the clinical diagnosis of T2DM (≥ 126 mg/dl) and prediabetes (≥ 100 mg/dl) are based on an extensive evidence base linking these thresholds to risks of various adverse outcomes 36 . However, this evidence is based primarily on FPG exposures from midlife onward, and late-life cognitive decline was not considered when determining the thresholds. Among older adults, FPG at the high end of the normal range ("high-normal FPG") may be associated with reduced brain tissue volumes and increased rates of brain atrophy. 37, 38 Among children, high-normal FPG may be associated with poorer beta cell function concurrently 39, 40 and in the future 41 . But there is little data relating FPG to brain outcomes to determine whether current clinical thresholds are adequate to identify individuals at increased risk of cognitive decline.
This study assesses the associations between FPG at different stages of the lifespan and cognition-relevant MRI markers of midlife brain health 21, 22, 42, 43 , and assesses the adequacy of current clinical thresholds to identify individuals whose glycemic status is associated with an increased risk of adverse brain outcomes, using data from the Bogalusa Heart Study (BHS).
Materials and Methods

Study sample.
The BHS began in 1973 as a community-based cohort study of atherosclerosis and risk factors for cardiovascular disease in a bi-racial population of children in a semi-rural town in southeastern Louisiana 44 . Most participants enrolled as children, and many attended regular follow-up visits through adulthood. Between 2013 and 2016, cognitive tests were administered for the first time to 1,298 participants. Inclusion criteria for this study included prior participation in BHS, completion of cognitive testing, lack of MRI contraindications, and right handedness (to prevent confounding effects of handedness on completion of fMRI tasks). A CONSORT diagram is shown in Figure 1 . Briefly, the 1298 individuals who completed cognitive testing previously were contacted about this project via mailed flyers. From that group, 74 individuals completed screening procedures and 9 were deemed ineligible due to MRI contraindication or left-handedness. Of the remaining 65 individuals, 50 completed the required MRI; 2 failed to arrive for the MRI; 1 had to halt the MRI early due to claustrophobia; and 12 were ready to be scheduled for MRI at the time the study reached its target of 50 completers. Participants in this study provided informed consent. The study was overseen by the Institutional Review Board of Pennington Biomedical Research Center.
Physiological measures.
Measurement of FPG and insulin have been described previously [45] [46] [47] . Both were measured following a standardized protocol at a centralized laboratory. FPG were analyzed by an enzymatic method using the Beckman glucose analyzer 48 . Plasma insulin concentrations were measured using a radioimmunoassay procedure (Phadebas; Pharmacia Diagnostics, Piscataway, NJ).
MRI acquisition.
Brain MRI scans were performed on a GE Discovery 3T scanner at Pennington Biomedical Research Center. A 32-channel phased array head coil was used. Our Stroop task tested inhibitory control in the context of negative feedback and time-pressured responses 50 . In each trial, for 400-5000 ms participants saw one probe word and four target words that were names of colors. The task was to identify the target word whose color matched that of the probe. In the congruent (incongruent) condition, word meaning matched (did not match) the color it was printed in. Correct (incorrect) responses on 3 consecutive incongruent trials prompted a 300 ms reduction (increase) in stimulus duration. Four 52-60 second incongruent trial blocks were interleaved with 4 congruent trial blocks, each of which had the same number of trials as the previous incongruent block. The inter-block interval was 10-17 seconds. Stroop task performance was summarized in terms of task accuracy (i.e., percent of trials answered correctly), mean reaction times to congruent and incongruent trials, and the so- Post-processing of structural MRI data follows techniques described previously [51] [52] [53] . Key FLAIR processing steps include manual removal of non-brain elements from the FLAIR image by operator guided tracing of the dura mater within the cranial vault, resulting in delineation of a total cranial volume (TCV) region; MRI non-uniformity correction of the TCV 54 ; thresholding of TCV into brain and non-brain tissues 55 ; fitting a single Gaussian distribution to the brain tissue intensity distribution and labeling of all voxels with intensity greater than 3.5 standard deviations above the mean as WMH 56 . Key T1-weighted image processing steps include MRI non-uniformity correction 57 ; and segmentation of gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF) by a Bayesian maximum-likelihood expectation-maximization algorithm 58 . The primary measures of interest in subsequent analysis were volumes of WMH, GM, and WM, each expressed as a percentage of TCV.
fMRI data preprocessing.
Preprocessing of fMRI included slice timing correction, head motion correction, smoothing, coregistration to the T1-weighted image, and warping T1-weighted data to a standard coordinate frame (using Statistical Parametric Mapping 12). Cardiac and respiratory time series were regressed out of the data using RETROICOR 49 . Time points with excess head rotation (>1.5 degrees) or translation (1.5 mm) were removed from analysis. Voxel time series were entered into a first-level general linear model, where the experimental design was modeled as boxcar functions convolved with the canonical hemodynamic response function.
fMRI activation analysis.
The inhibitory control contrast was measured between congruent and incongruent blocks in the Stroop task. Data from incorrect, missing, or pre-attentive (i.e., < 200 ms) responses were removed from analysis. The 3D coordinates of ROIs that repeatably show fMRI signal differences in this version of the Stroop task under the inhibitory control contrast (covering occipital, fusiform, angular, middle frontal, inferior frontal, superior frontal, cingulate, and middle temporal gyri; and within the cerebellum, precuneus, insula, lentiform nucleus, thalamus) were identified from a published report 50 . The mean beta value for the inhibitory control contrast among all voxels in an 3-mm-radius sphere centered at each ROI location was calculated. Principal components analysis (PCA) was then applied to the set of all ROI means. PCA is a dimension reduction technique that reduces a given large set of measurements (in this case the ROI means) to a smaller number of numbers (the PCA coefficients) that, together, explain the greatest amount of variability in the measurements. We reduced each set of ROI means to a single PCA coefficient that provided a univariate summary of the overall level of activation of all ROIs under the inhibitory control contrast (referred to hereafter as "Stroop activation").
Statistical analysis.
Statistical analysis focused on summarizing FPG within different epochs of the lifespan, and relating FPG within those epochs to MRI outcome measures. We separated all FPG measurements into three epochs: those collected before age 20 ("pre-20"), between ages 20 and 40 ("20-40"), and after age 40 ("over-40"). For each individual, the mean FPG within each epoch was calculated. The median pre-20 mean FPG was then calculated, and mean FPG values were categorized in terms of whether they were below this threshold ("low-normal") or above it. The range of mean FPG values above the threshold is referred to as "high-normal" in the pre-20 62 . Demographic variables, cardiometabolic variables, and cognitive measurements were largely similar in this group compared to the broader set of BHS participants they were sampled from ( Table 1 ). The current group displayed higher scores on the Digit Coding test than the broader sample did, and had provided a relatively larger number of FPG measurements during the 20-40 epoch. The current group had relatively lower representation of male participants and African American participants than the broader sample did.
Glycemic trajectories.
Trajectories of FPG over time for each participant are plotted in Figure 2 , along with boundaries between epochs, accepted thresholds for the diagnosis of prediabetes (≥ 100 mg/dl) and T2DM (≥ 126 mg/dl), and the median pre-20 mean FPG value used to define the low-normal group. Table 2 . Stroop task accuracy (mean 69% +/-standard deviation 9.1%) was similar to that seen in one prior study utilizing the same, adaptive version of the task 50, 63 . Mean reaction time (1645 +/-617 ms) was also in line with that of a prior publication 63 . None of the performance measures were associated with mean FPG status in the pre-20 or 20-40 epochs, in models that controlled for sex, race, and age at the time of MRI scan (all p>.05). Scores on none of the cognitive tests were associated with mean FPG status in any epoch (all p>.05).
Discussion
In this study, middle-aged, Deep Southern, semi-rural individuals who during early adolescence had exhibited mean FPG in the high-normal range (i.e., above a low-normal threshold, but still below the accepted cutoff for prediabetes) showed signs of poorer MRI-based markers of brain health in midlife, even after controlling for midlife FPG, suggesting a persistent legacy effect of pre-20 glycemic status as a risk marker. There are two key implications of this finding. First, it reinforces the importance of elevated early-life FPG as a risk marker by identifying poorer midlife brain health as another possible outcome of it 64, 65 66 . Second, it suggests that established clinical thresholds for T2DM (FPG ≥ 126 mg/dl) and prediabetes (≥ 100 mg/dl) may be inadequate to identify adolescents with an increased risk of poorer midlife brain health.
The finding that early-life FPG may be associated with brain health decades later adds to a growing literature suggesting that early life experiences influence health outcomes later in life [31] [32] [33] [34] . This literature points to critical periods during which exposure to environmental or physiologic stimuli induces "programming" of a fixed future aspect of organ function 35 . Differing brain regions grow at different paces during the first three decades of life 67 , and complex hormonal signaling events modulate those trajectories [68] [69] [70] [71] . Because insulin-and glucose-related signaling molecules are involved in brain growth and maturation [72] [73] [74] [75] [76] , it is plausible that metabolic disturbances associated with elevated FPG could result in consequences for brain development proximally as well as years into the future. Testing this hypothesis will require longitudinal series of brain and metabolic measures collected throughout adolescence, young adulthood, and midlife. A striking aspect of our findings is that no early-life mean FPG values were in the prediabetes or T2DM range. Individuals who had "high-normal" mean FPG values in that epoch (greater than 83.5 mg/dl, less than 100 mg/dl) had greater WMH volume and less brain activation to a cognitive task. Increased risks of poorer outcomes among those with high-normal FPG has been reported previously, 37, , although large-scale epidemiological data including adolescent and midlife data is highly limited. Our study was too small to determine whether midlife brain outcomes scaled continuously and linearly with adolescent mean FPG across the entire normal range, or whether there is a critical threshold value above which poorer brain outcomes are especially probable. Large-scale studies of these questions are needed, because an association between high-normal adolescent FPG and adverse midlife outcomes could in the long run trigger a shift in clinical practice toward identifying such individuals and intervening early to lower FPG.
Associations between mean FPG and midlife brain outcomes were similar within adolescent and early adulthood epochs, with two notable differences. First, midlife gray matter volume was associated with FPG status only in young adulthood. Prior studies suggest that gray matter deficits, representing cell death, represent a final common pathway that can follow multiple modes of cell distress, including lesion formation (represented by WMHs) and neuronal dysfunction (represented by fMRI) 21, [77] [78] [79] . Thus, if the young adults high-normal or impaired mean FPG were exposed to a greater duration or severity of brain injury processes than corresponding adolescents, we would expect gray matter deficits to appear only in the young adults. Second, while associations between high-normal mean FPG in the adolescent epoch and poorer midlife brain outcomes remained significant after controlling for midlife FPG status, the same was not true of high-normal or impaired mean FPG in the young adulthood epoch. This suggests that the young adults with high-normal or impaired mean FPG may simply be ones who go on to have elevated FPG in midlife and thus might have poorer brain health due to midlife status alone. A larger study is needed to determine the degree to which both epochs of the lifespan are independently associated with midlife brain outcomes.
The key strength of this study is its utilization of lifespan data from a large, communitybased, bi-racial, Deep Southern, semi-rural epidemiological cohort. The key limitation is its lack of brain MRI concurrent with early-life FPG. This limitation was unavoidable-functional MRI did not become available until roughly 20 years after the first FPG measurement. Our small sample size and lack of other glycemic measures such as hemoglobin A1C (which also was not widely utilized until long after cohort initiation) are additional limitations.
In conclusion, individuals with mean FPG at the high end of the normal range during adolescence went on to exhibit more WMHs and less fMRI activation during a cognitive task at midlife, independent of midlife mean FPG. 
